IDEAYA Biosciences (NASDAQ:IDYA) Raised to Hold at The Goldman Sachs Group

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) was upgraded by analysts at The Goldman Sachs Group to a "hold" rating in a research note issued on Thursday, MarketBeat.com reports. The firm currently has a $25.00 price objective on the stock. The Goldman Sachs Group's price target indicates a potential upside of 11.21% from the stock's previous close.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research report on Thursday, May 22nd. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Finally, Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the company from $57.00 to $30.00 in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.55.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded down $0.32 during trading hours on Thursday, reaching $22.48. The company had a trading volume of 804,315 shares, compared to its average volume of 993,697. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $44.42. The business has a fifty day simple moving average of $20.54 and a 200-day simple moving average of $20.44. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -6.26 and a beta of 0.03.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the company posted ($0.53) earnings per share. On average, equities research analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Institutional Trading of IDEAYA Biosciences

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in IDEAYA Biosciences in the fourth quarter worth $47,000. CWM LLC increased its position in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares in the last quarter. Finally, Signaturefd LLC grew its position in shares of IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after purchasing an additional 2,271 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.